Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol.
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
18 Apr 2019
18 Apr 2019
Historique:
received:
17
08
2018
accepted:
09
04
2019
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
6
5
2020
Statut:
epublish
Résumé
Cerebral venous thrombosis causes disability from venous infarct and hemorrhage and potential mortality. Anticoagulation improves survival and disability outcomes, yet direct oral anticoagulants are currently not indicated in cerebral venous thrombosis due to lack of evidence, despite being on the market for nearly a decade. This systematic review will collate evidence of reported safety and efficacy of direct oral anticoagulant therapy in cerebral venous thrombosis. A search strategy was developed with a research librarian and registered on a protocol database (PROSPERO CRD42017078398). All published studies from MEDLINE and EMBASE up to February 2019 containing patients diagnosed with cerebral venous thrombosis who were treated with a direct oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) will be included. A risk of bias analysis will be performed to evaluate quality of studies overall. Current guidelines in the treatment of cerebral vein thrombosis dating back to 2011 from the American Heart Association/American Stroke Association endorse the utility of anticoagulation for the treatment of cerebral vein thrombosis; however, they did not support the use of direct oral anticoagulants. Updated guidelines from the European Stroke Organization, endorsed by the European Academy of Neurology in 2017, also refute utilization of direct oral anticoagulants due to a lack of evidence. There have been nearly 10 years of experience with direct oral anticoagulants in the treatment of venous thrombosis and prevention of stroke in patients with atrial fibrillation, with purported efficacy and safety in comparison with heparins and vitamin K antagonists. Our goal is to undertake a systematic review to assess the effectiveness and safety of direct oral anticoagulants in patients with cerebral vein thrombosis to help guide clinical decision-making for patients unable to take heparins or vitamin K antagonists and to direct future studies to contribute further to an area of certain evidence-based needs. PROSPERO CRD42017078398.
Sections du résumé
BACKGROUND AND PURPOSE
Cerebral venous thrombosis causes disability from venous infarct and hemorrhage and potential mortality. Anticoagulation improves survival and disability outcomes, yet direct oral anticoagulants are currently not indicated in cerebral venous thrombosis due to lack of evidence, despite being on the market for nearly a decade. This systematic review will collate evidence of reported safety and efficacy of direct oral anticoagulant therapy in cerebral venous thrombosis.
METHODS
A search strategy was developed with a research librarian and registered on a protocol database (PROSPERO CRD42017078398). All published studies from MEDLINE and EMBASE up to February 2019 containing patients diagnosed with cerebral venous thrombosis who were treated with a direct oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) will be included. A risk of bias analysis will be performed to evaluate quality of studies overall.
DISCUSSION
Current guidelines in the treatment of cerebral vein thrombosis dating back to 2011 from the American Heart Association/American Stroke Association endorse the utility of anticoagulation for the treatment of cerebral vein thrombosis; however, they did not support the use of direct oral anticoagulants. Updated guidelines from the European Stroke Organization, endorsed by the European Academy of Neurology in 2017, also refute utilization of direct oral anticoagulants due to a lack of evidence. There have been nearly 10 years of experience with direct oral anticoagulants in the treatment of venous thrombosis and prevention of stroke in patients with atrial fibrillation, with purported efficacy and safety in comparison with heparins and vitamin K antagonists. Our goal is to undertake a systematic review to assess the effectiveness and safety of direct oral anticoagulants in patients with cerebral vein thrombosis to help guide clinical decision-making for patients unable to take heparins or vitamin K antagonists and to direct future studies to contribute further to an area of certain evidence-based needs.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42017078398.
Identifiants
pubmed: 30999965
doi: 10.1186/s13643-019-1022-8
pii: 10.1186/s13643-019-1022-8
pmc: PMC6474061
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Références
N Engl J Med. 2009 Dec 10;361(24):2342-52
pubmed: 19966341
Int J Stroke. 2015 Oct;10(7):1115-8
pubmed: 25708372
Ther Clin Risk Manag. 2015 Jun 24;11:967-77
pubmed: 26150723
Eur J Neurol. 2017 Oct;24(10):1203-1213
pubmed: 28833980
Stroke. 2004 Mar;35(3):664-70
pubmed: 14976332
Syst Rev. 2019 Apr 18;8(1):99
pubmed: 30999965
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Lancet. 1991 Sep 7;338(8767):597-600
pubmed: 1679154
Int J Stroke. 2018 Oct;13(7):766-770
pubmed: 29775170
Stroke. 2014 Aug;45(8):2469-71
pubmed: 25070963
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Stroke. 2011 Apr;42(4):1158-92
pubmed: 21293023
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Cochrane Database Syst Rev. 2011 Aug 10;(8):CD002005
pubmed: 21833941